Due to its cytotoxic effect in lymphoid cells, dexamethasone is widely used in the treatment of Multiple Myeloma. However, only a subset of myeloma patients responds to high-dose dexamethasone. Despite the undeniable anti-myeloma benefits of dexamethasone, significant adverse effects have been reported. The anti-tumor effect of dexamethasone was re-evaluated according to the molecular heterogeneity of Multiple Myeloma.
Myelomax is a preclinical CRO specializing in Multiple Myeloma target candidate testing and evaluation services for pharmaceutical and biotech companies, and research organizations who are working to advance therapies for Multiple Myeloma.